AC Immune (NASDAQ:ACIU) Stock Has Average Price Target of $7.50

Shares of AC Immune (NASDAQ:ACIU) have been assigned a consensus recommendation of “Moderate Buy” from the five brokerages that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, three have issued a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $7.50.

Several brokerages have recently issued reports on ACIU. BTIG Research reaffirmed a “buy” rating and issued a $8.00 target price on shares of AC Immune in a research note on Wednesday, September 23rd. HC Wainwright reissued a “buy” rating on shares of AC Immune in a research note on Thursday, September 24th. Weiss Ratings restated a “sell (e+)” rating on shares of AC Immune in a report on Wednesday, August 5th. Finally, Zacks Research raised shares of AC Immune from a “hold” rating to a “strong-buy” rating in a research note on Tuesday.

AC Immune Stock Up 0.8%

NASDAQ ACIU opened at $2.62 on Thursday. The stock has a fifty day moving average of $2.59 and a 200-day moving average of $2.67. The stock has a market capitalization of $266.64 million, a P/E ratio of -4.85 and a beta of 1.60. AC Immune has a 52 week low of $2.10 and a 52 week high of $4.00. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.02 and a current ratio of 0.93.

AC Immune (NASDAQ:ACIU) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.03 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.13. The business had revenue of $18.67 million for the quarter, compared to analysts’ expectations of $9.59 million. AC Immune had a negative return on equity of 100.17% and a negative net margin of 245.32%. On average, equities research analysts forecast that AC Immune will post -0.6 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. AXQ Capital LP acquired a new stake in shares of AC Immune during the second quarter worth $25,000. Arrowstreet Capital Limited Partnership lifted its stake in AC Immune by 8.0% in the first quarter. Arrowstreet Capital Limited Partnership now owns 405,658 shares of the company’s stock valued at $1,116,000 after buying an additional 30,035 shares during the period. Finally, Dimensional Fund Advisors LP boosted its holdings in AC Immune by 82.8% during the first quarter. Dimensional Fund Advisors LP now owns 390,165 shares of the company’s stock worth $1,071,000 after buying an additional 176,701 shares during the last quarter. 51.36% of the stock is currently owned by institutional investors.

About AC Immune

AC Immune SA (NASDAQ: ACIU) is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland. Founded in 2003, the company develops precision medicines and diagnostic products designed to prevent, diagnose and treat neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease and other conditions associated with misfolded proteins.

AC Immune’s research is based on its SupraAntigen and Morphomer technology platforms, which are intended to identify disease-related proteins and generate therapies or diagnostic tools that target them.